INTRODUCTION {#sec0001}
============

Since December 2019, the outbreak of coronavirus disease 2019 (COVID-19) has rapidly become a public concern, with more than 13,287,651 confirmed cases and 577,954 deaths as of July 15, 2020.[@bib0001] Coexistence of COVID-19 and cardiovascular diseases (CVD) is often associated with poor prognosis.[@bib0002] Once myocardial injury occurs, patients infected with COVID-19 are at high risk for severe conditions and admission to intensive-care unit (ICU).[@bib0003] In addition, patients with CVD account for a large proportion of deaths from COVID-19.[@bib0004] Patients with acute coronary syndrome are more likely to suffer sudden deterioration in medical condition with concomitant COVID-19 due to reduced cardiac function caused by myocardial ischemia or necrosis.[@bib0005]

ST-segment elevation myocardial infarction (STEMI) is an emergent CVD and requires timely primary reperfusion therapy (mainly primary percutaneous coronary intervention \[PCI\]).[@bib0006], [@bib0007], [@bib0008] The public health emergency response for COVID-19 had significant impact on the healthcare system for STEMI globally. Nearly 27% decline of STEMI admissions was reported in Italy[@bib0009] and Australia[@bib0010], as well as a 38% reduction in US cardiac catheterization laboratory STEMI activations[@bib0011]. In China, hospitals are divided into designated hospitals for treating patients with diagnosed COVID-19, and non-designated hospitals for those without COVID-19 infection. In non-designated hospitals, to minimize infection risk among medical staffs and nosocomial transmission, cutting down on the number of primary PCI and choosing a more conservative approach is unavoidable. The present study aimed to clarify the impact of public health emergency response for COVID-19 on in-hospital management and outcomes for STEMI patients.

METHODS {#sec0002}
=======

Study Population {#sec0003}
----------------

We enrolled all the STEMI patients with ischemic symptoms duration ≤48 h at presentation to the emergency department at Fuwai Hospital from January 24^th^ to March 31^st^ during the COVID-19 epidemic in Beijing, China. We also included all consecutive STEMI patients who were treated at Fuwai Hospital between January 24^th^ and March 31^st^ in 2019 as historical control. This study was approved by the ethics committee of Fuwai Hospital.

Treatment Principles for STEMI during COVID-19 Epidemic {#sec0004}
-------------------------------------------------------

Detailed classification criteria and corresponding management protocols for STEMI patients are described in the Supplementary Appendix. In brief, patients with confirmed or suspected COVID-19 according to the COVID-19 Diagnosis and Treatment (7^th^ edition)[@bib0012] should be transferred to COVID-19-designated-hospitals and receive medical therapy as soon as possible. Patients in whom COVID-19 cannot be ruled out temporarily , defined as the absence of epidemiological history of COVID-19, with 1-2 clinical manifestations of COVID-19, but not fulfilling diagnostic criteria for COVID-19, should be transferred to designated clinics and treated with medical therapy, and at the same time screened for COVID-19 and transferred to designated hospitals if test is positive.[@bib0013] Excluded patients are defined as having a clinical very small risk of COVID-19 infection, which included the absence of fever, respiratory symptoms, decreased WBC count and epidemiological exposure to other COVID-19 cases or areas with cluster transmission.

Algorithm for Management of STEMI Patients ([Figure 1](#fig0001){ref-type="fig"}) {#sec0005}
---------------------------------------------------------------------------------

Detailed management algorithm of STEMI patients during COVID-19 pandemic in our institution are described in the supplemental material. In brief, medical staffs firstly assessed whether COVID-19 could be ruled out clinically. For patients who can be ruled out for COVID-19 infection and within 12 hours after symptom onset, with no contraindications and would benefit from thrombolysis, thrombolytic therapy should be initiated immediately. For patients with thrombolytic contraindications, failed thrombolysis, who would not benefit from thrombolysis or presenting \>12 hours after symptom onset, a comprehensive benefit-risk evaluation of primary PCI is required. For patients who can\'t be ruled out for COVID-19 infection, all medical activity should start in designated screening room.

Data Collection and Adverse Clinical Event Definitions {#sec0006}
------------------------------------------------------

All data were obtained by screening patient medical document. The primary outcome was defined as a composite endpoint of all-cause death, cardiac shock, cardiac arrest and heart failure during hospitalization . Diagnostic criteria for recurrent myocardial infarction was in accordance with the fourth universal definition of myocardial infarction, when cardiac troponin (cTn) value is above the 99th percentile upper reference limit and at least one of the following characteristics: 1) presentation of myocardial symptoms; 2) new ischemic ECG changes or development of pathological Q waves[@bib0014]. We also studied each individual component of the primary outcome and other two clinical outcomes including mechanical complication and arrhythmia . Arrhythmia included atrial fibrillation, atrial flutter, ventricular tachycardia, atrioventricular block and sinus arrest. Mechanical complication was defined as rupture of ventricular wall, ventricular septum, or papillary muscle. Two cardiologists independently adjudicated all events by using original source documents.

Statistical Analysis {#sec0007}
--------------------

Continuous data are expressed as mean ± SD or median (interquartile range) and categorical variables are presented as counts and percentages. The continuous variables were compared using the Student t test or the Wilcoxon signed-rank test, as appropriate. The categorical variables were compared by the likelihood ratio chi-square or the Fisher exact test. Logistic regression model was used to calculate odds ratio (OR) and 95% confidence intervals (CI) for clinical adverse events according to the year of hospitalization. A total of three multivariate models with different level of adjustment were used: Model 1 was adjusted for age and sex, model 2 was additionally adjusted for previous myocardial infarction and previous renal insufficiency. Model 3 was further adjusted for time from symptom to hospital. All statistical analyses were performed with SAS 9.4(SAS Institute, Cary, NC, USA).

RESULTS {#sec0008}
=======

During the COVID-19 epidemic in China from January 24^th^ to March 31^st^, 2020, a total of 73 consecutive patients presenting to the emergency department at Fuwai Hospital within 48 hours after ischemia symptoms onset were diagnosed with STEMI. During the same period in 2019, a total of 95 consecutive STEMI patients arrived at the emergency department at Fuwai Hospital within 48 hours after symptoms onset. As expected, compared with year 2019, the proportion of patients receiving primary PCI significantly reduced (77.6% reduction, 95% CI: 66.6%-88.5%, p\<0.01), and the proportion of thrombolytic therapy (20.6% increase, 95% CI: 10.1%-31.0%, p\<0.01) and medical therapy (57.0 % increase, 95% CI: 43.6%-70.4%, p\<0.01) increased ( [Figure 2](#fig0002){ref-type="fig"} ). Detailed reasons for not receiving thrombolysis and primary PCI for STEMI patients in 2020 are described in the Supplementary Appendix. In brief, for patients within 12 hours after symptom onset, the primary reasons were improvement in symptoms (\>50% ) and ST-segment return on ECG, advanced age, relative contradiction of thrombolysis or refusal by patients' family members after learning about potential related risks. For patients \>12 hours after symptom onset, the main reasons were symptoms improved and ST-segment return on ECG, or refusal by patients' family members after consultation with the medical staff about the risk and benefit of PCI.Figure 1Algorithm for Management of STEMI Patients for Non-designated Hospital during COVID-19 Epidemic. Medical staff should firstly evaluate whether COVID-19 can be excluded. For patients with a clinical small risk of COVID-19 infection, within 12 hours after symptom onset, with no contradiction and will possibly gain benefit, thrombolysis should be initiated immediately. For patients with thrombolytic contraindications or failed thrombolysis, a comprehensive benefit-risk assessment should be performed, and primary PCI should be started immediately when appropriate. For patients who cannot be ruled out for COVID-19 infection temporarily, all medical practice and COVID-19 screening should be conducted simultaneously.COVID-19 = coronavirus disease 2019; CAG = coronary angiography; CT = computed tomography; ECG = electrocardiogram; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction.Figure 1Figure 2Impact of public health emergency response for COVID-19 on in-hospital outcome and treatment strategy. During COVID-19 pandemic, there was a 23.2% reduction in STEMI admission and 77.6% reduction in the number of primary PCI compared with historic control.STEMI = ST-elevation myocardial infarction; PCI = percutaneous coronary intervention.Figure 2

Other baseline and clinical characteristics of the total study population are shown in [Table 1](#tbl0001){ref-type="table"} . There were no significant differences in baseline and clinical characteristics between groups.Table 1Baseline and Clinical Characteristics of STEMI Patients according to the Year of HospitalizationTable 1VariableYear 2020 (N=73)Year 2019 (N=95)Difference (95% CI)P valueAge (y)61.6±13.160.6±13.91.0 (-3.2, 5.1)0.65Female14 (19.2)27 (28.4)-9.5 (-23.3, 4.8)0.17Hypertension43 (58.9)56 (59.0)-0.04 (-16.3, 16.2)1.00Hyperlipidemia39 (53.4)51 (53.7)-0.3 (-16.7, 16.2)0.97Current smoking36 (49.3)55 (57.9)-8.6 (-25.0, 7.8)0.27Diabetes mellitus16 (21.9)22 (23.2)-1.2 (-15.2, 12.7)0.85Previous MI7 (9.6)5 (5.3)4.3 (-5.0, 13.7)0.28Previous PCI7 (9.6)9 (9.5)0.1 (-10.1, 10.3)0.98Previous CABG2 (2.7)2 (2.1)0.6 (-5.3, 6.6)1.00Previous stroke10 (13.7)12 (12.6)1.1 (-10.5, 12.6)0.84Previous heart failure2 (2.7)2 (2.1)0.6 (-5.3, 6.6)1.00Previous renal insufficiency05 (5.3)-5.3 (-11.0, 0.4)0.07Heart rate76.0±19.975.8±18.40.2 (-5.8, 6.2)0.95Systolic BP (mmHg)134.3±23.4131.3±23.73.0 (-4.4, 10.3)0.43Diastolic BP(mmHg)81.6±15.978.2±16.73.3 (-1.8, 8.4)0.20LV(mm)50.0±5.249.2±5.10.8 (-0.8, 2.4)0.34Ejection fraction (%)51.4±7.752.3±7.6-0.9 (-3.3, 1.5)0.45Primary value TNI (ng/ml)0.2 (0.04, 1.5)0.2 (0.05, 3.2)0.003 (-0.07, 0.11)0.88Peak value TNI (ng/ml)22.6 (8.4, 44.0)23.0 (11.8,44.7)-2.9 (-8.6, 3.1)0.33Primary value NT-proBNP (pg/fl)199.0 (61.4, 553.0)153.2 (40.7, 723.0)-1.0 (-70.5, 56.4)0.96Peak value NT-proBNP (pg/fl)1927.0 (1074.0, 3511.0)1957.0 (921.6, 4014.0)-74.8 (-586.6, 456.8)0.78D-B time of primary PCI (min)122.5 (78.5, 187.5)106.0 (80.0, 138.0)16.0 (-7.0, 46.0)0.15Killip ClassificationI59 (80.8)82 (86.3)-5.5 (-18.1, 7.1)0.34II8 (11.0)10 (10.5)0.4 (-10.2, 11.1)0.93III2 (2.7)1 (1.1)1.7 (-3.8, 7.2)0.58IV4 (5.5)2 (2.1)3.4 (-3.8, 10.6)0.41Hours after symptom onset0-12h56 (76.7)70 (73.7)3.0 (-11.3, 17.4)0.6512h-24h10 (13.7)17 (17.9)-4.2 (-16.4, 8.0)0.4624h-48h6 (8.2)6 (6.3)1.9 (-7.3, 11.1)0.63**Type of AMI**Extensive anterior wall13 (17.8)22 (23.2)-5.4 (-18.8, 8.1)0.40Anterior wall19 (26.0)20 (21.1)5.0 (-9.2, 19.2)0.45Inferior wall41 (56.2)47 (49.5)6.7 (-9.7, 23.1)0.39High lateral wall06 (6.3)-6.3 (-12.4, -0.2)0.04**Clinical therapy**Primary PCI11 (15.1)88 (92.6)-77.6 (-88.5, -66.6)\<0.01Thrombolytic therapy15 (20.6)020.6 (10.1, 31.0)\<0.01Medical treatment47 (64.4)7 (7.5)57.0 (43.6, 70.4)\<0.01[^2]

A comparison of adverse clinical events during hospitalization between patients in the two groups is shown in [Table 2](#tbl0002){ref-type="table"} . Patients enrolled during COVID-19 pandemic had a trend toward higher rate of composite endpoint (15.1 % vs. 11.6%, rate difference 3.5% \[95% CI: -8.2%, 15.1%\], p=0.51), and higher rate of most other adverse events than historic control ([Figure 3](#fig0003){ref-type="fig"} ). In-hospital adverse clinical outcomes after primary PCI in the two groups are shown in the Supplementary Appendix Table S1. Angiographic characteristics and TIMI flow grade in patients enrolled in 2020 are shown in the Supplementary Appendix Table S2.Table 2In-hospital Clinical Adverse Events of Patients according to the Year of HospitalizationTable 2Adverse eventYear 2020 (N=73)Year 2019 (N=95)Difference (95% CI) (%)P valueComposite endpoint11 (15.1)11 (11.6)3.5 (-8.2, 15.1)0.51Death2 (2.7)2 (2.1)0.6 (-5.3, 6.6)1.00Heart failure8 (11.0)9 (9.5)1.5 (-9.0, 12.0)0.75Cardiac arrest3 (4.1)2 (2.1)2.0 (-4.6, 8.6)0.65Cardiac shock4 (5.5)4 (4.2)1.3 (-6.5, 9.1)0.73Recurrent MI7 (9.6)8 (8.4)1.2 (-8.8, 11.1)0.79Mechanical complication01 (1.1)-1.1 (-4.3, 2.2)1.00Arrhythmia17 (23.3)16 (16.4)6.5 (-7.0, 19.9)0.30[^3]Figure 3Rate of Adverse Clinical Events according to the Year of HospitalizationMI = myocardial infarction.Figure 3

[Table 3](#tbl0003){ref-type="table"} shows the results of univariate and multivariate logistic regression analyses. Hospitalization during COVID-19 pandemic was associated with trend towards higher risk of composite endpoint (OR: 1.35 95% CI: 0.52, 3.51) compared with historic control, after adjustment of age, sex, previous MI and renal insufficiency, and time from symptom to hospital. Similarly, there was a trend towards higher risk of each in-hospital individual adverse events during COVID-19 pandemic than historic control. [Table 4](#tbl0004){ref-type="table"} shows the comparison of baseline and clinical characteristics between non-reperfusion and reperfusion patients in STEMI cases enrolled in 2020. More extensive anterior AMI was found in reperfusion patients (8.5% vs. 34.6%, p=0.01). Clinical outcomes between non-reperfusion and reperfusion STEMI patients hospitalized in 2020 are shown in [Table 5](#tbl0005){ref-type="table"} . Compared with reperfusion group, patients who did not receive emergent reperfusion therapy had a trend towards higher rate of composite endpoint (19.2% vs. 7.7%, rate difference: 11.5% \[95%CI: -6.7%, 29.7%\], p=0.31) and other adverse events during hospitalization.Table 3Association between the Year of Hospitalization with Adverse Clinical EventsTable 3Adverse eventsUnivariate modelMultivariate ModelModel 1Model 2Model 3OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)Composite endpoint1.36 (0.55, 3.33)1.37 (0.55, 3.41)1.35 (0.52, 3.51)1.35 (0.52, 3.51)Death1.31 (0.18, 9.53)1.21 (0.16, 9.07)2.10 (0.17, 26.61)2.25 (0.18, 28.18)Heart failure1.18 (0.43, 3.21)1.23 (0.43, 3.52)1.16 (0.37, 3.58)1.10 (0.35, 3.46)Cardiac arrest1.99 (0.32, 12.25)1.98 (0.31, 12.53)4.68 (0.43, 50.58)4.40 (0.40, 48.70)Cardiac shock1.32 (0.32, 5.46)1.20 (0.29, 5.05)1.51 (0.32, 7.17)1.53 (0.32, 7.22)Recurrent MI1.15 (0.40, 3.34)1.35 (0.45, 4.09)1.32 (0.43, 4.01)1.31 (0.43, 4.02)Mechanical complicationNANANANAArrhythmia1.50 (0.70, 3.22)1.44 (0.66, 3.14)1.44 (0.65, 3.18)1.44 (0.65, 3.19)[^4][^5][^6][^7]Table 4Baseline and Clinical Characteristics of Patients Enrolled in 2020 according to Reperfusion TreatmentTable 4VariableNon-reperfusion Group (N=47)Reperfusion Group (N=26)Difference (95% CI)P valueAge (y)63.1±13.958.8±11.24.3 (-2.0, 10.7)0.18Female9 (19.2)5 (19.2)-0.1 (-21.9, 21.8)1.00Hypertension29 (61.7)14 (53.9)7.9 (-18.8, 34.5)0.51Hyperlipidemia26 (55.3)13 (50.0)5.3 (-21.6, 32.2)0.66Current smoking22 (46.8)14 (53.9)-7.0 (-33.9, 19.8)0.56Diabetes mellitus13 (27.7)3 (11.5)16.1 (-4.6, 36.8)0.11Previous MI4 (8.5)3 (11.5)-3.0 (-20.7, 14.6)0.69Previous PCI4 (8.5)3 (11.5)-3.0 (-20.7, 14.6)0.69Previous CABG2 (4.3)04.3 (-4.5, 13.0)0.54Previous stroke5 (10.6)5 (19.2)-8.6 (-29.1, 11.9)0.31Previous heart failure2 (4.3)04.3 (-4.5, 13.0)0.54Previous renal insufficiency000Heart rate74.9±20.277.8±19.5-2.9 (-12.7, 6.8)0.55Systolic BP (mmHg)135.9±23.6131.3±23.34.6 (-6.8, 16.1)0.42Diastolic BP (mmHg)81.2±16.182.3±15.9-1.1 (-8.9, 6.7)0.78Initial LV (mm)50.3±6.149.4±3.30.92 (-1.3, 3.1)0.40Last LV (mm)51.4±5.350.7±3.80.68 (-1.7±3.1)0.55Initial ejection fraction (%)51.4±7.651.4±7.90.04 (-3.7, 3.8)0.98Last ejection fraction (%)52.0±10.852.5±5.5-0.5 (-4.5, 3.6)0.81Primary value TNI (ng/ml)0.4 (0.04,1.6)0.2 (0.04, 1.28)0.03 (-0.1, 0.48)0.58Peak value TNI (ng/ml)15.8 (6.0, 27.1)44.5 (24.9, 50.0)-20.3 ( -29.8, -11.3)\<0.01Primary value NT-proBNP (pg/fl)258.0 (79.7, 672.0)97.9 (28.7, 244.9)94.2 (-2.3, 275.2)0.06Peak value NT-proBNP (pg/fl)1993.0 (795.8, 4434.0)1862.0 (1448.0, 2929.0)125.5 (-709.7, 1064.0)0.69Hours after symptom onset0-12h31 (66.0)25 (96.2)-30.2 (-48.6, -11.8)\<0.0112h-24h9 (19.2)1 (3.9)15.3 (-1.1, 31.8)0.0924h-48h6 (12.8)012.8 (0.002, 0.25)0.08Type of AMIExtensive anterior wall4 (8.5)9 (34.6)-26.1 (-49.0, -3.2)0.01Anterior wall14 (29.8)5 (19.2)10.6 (-12.4, 33.6)0.32Inferior wall29 (61.7)12 (46.2)15.6 (-11.1, 42.2)0.20Lateral wall0 (0)0 (0)0NAKillip classificationI36 (76.6)23 (88.5)-11.9 (-32.1, 8.4)0.35II7 (14.9)1 (3.9)11.1 (-4.5, 26.6)0.25III2 (4.3)04.3 (-4.5, 13.0)0.54IV2 (4.3)2 (7.7)-3.4 (-18.2, 11.3)0.61[^8]Table 5Clinical Adverse Events during Hospitalization of Patients Enrolled in 2020 according to Reperfusion TreatmentTable 5Adverse EventNon-reperfusion Group (N=47)Reperfusion Group (N=26)Difference (95% CI)P valueComposite endpoint9 (19.2)2 (7.7)11.5 (-6.7, 29.7)0.31Death2 (4.3)04.3 (-4.5, 13.0)0.54Heart failure7 (14.9)1 (3.9)11.1 (-4.5, 26.6)0.25Cardiac arrest2 (4.3)1 (3.9)0.4 (-12.0, 12.8)1.00Cardiac shock4 (8.5)08.5 (-2.5, 19.5)0.29Recurrent MI6 (12.8)1 (3.9)8.9 (-6.1, 24.0)0.41Mechanical complication000Arrhythmia16 (34.0)1 (3.9)30.2 (11.8, 48.6)0.004[^9]

DISCUSSION {#sec0009}
==========

The present study reviewed clinical characteristics and in-hospital outcomes of the 73 STEMI patients at our hospital who received relatively conservative therapy during the peak of COVID-19 outbreak. Main findings were a significant reduction in the number of emergent reperfusion therapy and corresponding increase in conservative medical treatment during COVID-19 outbreak. Patients enrolled during COVID-19 pandemic had a trend towards higher risk of most clinical adverse events compared with historic control, particular for those who didn\'t receive timely reperfusion therapy.

It has been well established that timely reperfusion therapy (mainly primary PCI) is the cornerstone of STEMI therapy.[@bib0006] ^,^ [@bib0008] However, it is inevitable for non-designated hospitals to adopt relatively conservative STEMI management strategy during COVID epidemic to avoid and limit nosocomial transmission. In fact, it was estimated that there was a 38% reduction in US cardiac catheterization laboratory STEMI activations.[@bib0011] Our study also found a 77.6 % reduction in the number of primary PCI, and a corresponding 20.6% increase in thrombolytic therapy and a 57% increase in conservative medication therapy. a trend towards higher risk of most in-hospital clinical adverse events during COVID-19 pandemic. Our findings highlighted the potential unignorable adverse impact of COVID-19 pandemic on the efficient treatment of AMI. Failure of timely reperfusion not only negatively affects patients' in-hospital outcome, but also long-term prognosis due to larger infarction size and subsequent LV dysfunction[@bib0015]. In addition, a 23% reduction in STEMI admission was noticed. Patients failed to reach out to hospital were probably had subsequent higher mortality risk.

Although we observed an increasing trend in the rate of adverse events during COVID-19 pandemic, the increase was less significant than that of other studies. In Italy, case fatality rate of AMI increased from 2.8% in 2019 to 9.7% during COVID-19 pandemic[@bib0009]. In Hong Kong, in-hospital mortality rate of AMI increased from 5.9% in 2019 to 12.5% during the pandemic[@bib0016]. Main reasons included: (1) We performed timely reperfusion therapy, mainly thrombolytic treatment, in patients who may benefit the most from revascularization, with a short time to reperfusion and high successful thrombolysis rate. Another advantage associated with this strategy is the decreased need for repeated usage of cath lab for emergency procedure, which lowers the risk of nosocomial transmission and medical overuse. (2) The proportion of (extensive) anterior wall AMI was high in participants who received reperfusion therapy in 2020, which was higher than non-reperfusion group or historic control. Therefore, although the overall reperfusion rate in 2020 was lower than that in 2019, no significant difference in MACE was found between two years. (3) Most of the patients who did not receive thrombolysis or PCI had clinical signs of thrombus autolysis, or were unlikely to benefit from revascularization (see details in supplement). More importantly, the majority of these patients received revascularization during hospitalization.

Of note, not a single case of in-hospital infection occurred throughout the process of treatment among all STEMI patients at our hospital. Besides the low severity of COVID-19 epidemics in Beijing, the strict protective measures were the key contributor to the "zero nosocomial infection" rate. During COVID-19 pandemic, it is essential to be prepared in advance and set priorities for cath labs.[@bib0017] The key points of our institution\'s management algorithm include: (1) Timely initiation of reperfusion therapy under the premise of minimizing the risk of nosocomial transmission. (2) As for methods of revascularization, thrombolysis should be considered as the first choice and rescue PCI as an adjunctive. (3) All patients who cannot be ruled out for COVID-19 infection should be quarantined in a designated screening room, closely treated and screened. (4) All patients with confirmed or suspected COVID-19 should be transferred as quickly as possible and concurrently receive medical therapy.

Limitations {#sec0010}
-----------

The present study may be subject to the bias inherent to its retrospective non-randomized design. .However, baseline characteristics were comparable between study and historical control groups. The sample size was relatively small and all data were derived from a large single center. Finally, the current study investigated in-hospital adverse events with short-term (30-day) follow-up period. Whether this modified strategy affects patients' long-term outcome remains unclear.

CONCLUSIONS {#sec0011}
===========

Our preliminary data demonstrates that the public health emergency response for COVID-19 leads to a significant reduction in emergent reperfusion, and a corresponding trend towards higher risk of most adverse events during hospitalization, particular for patients who didn\'t receive timely reperfusion therapy. How to better balance the risks and benefits from STEMI management, under the premise of prevention and control of COVID-19 transmission, remains an unprecedented challenge and urgently requires future research action.
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